Research programme: tunable drug conjugates - OS Therapies
Alternative Names: OST-TDCLatest Information Update: 03 Mar 2023
At a glance
- Originator OS Therapies
- Class Antibodies; Antineoplastics; Biological toxins; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Jan 2023 Preclinical trials in Cancer in USA (Parenteral) (OS Therapies pipeline; January 2023)
- 24 Aug 2020 OS Therapies in-licenses Antibody Drug Conjugate technology from BlinkBio
- 25 Apr 2018 BlinkBioreceives patent allowance for SiLinker and payload cassette technologies of Tunable Drug Conjugates (TDCs) in USA